Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThis work is focused on the potential use of pulmonary surfactant to deliver full-length recombinant human surfactant protein SP-D (rhSP-D) using the respiratory air-liquid interface as a shuttle. Surfactant protein D (SP-D) is a collectin protein present in the pulmonary surfactant (PS) system, involved in innate immune defense and surfactant homeostasis. It has been recently suggested as a potential therapeutic to alleviate inflammatory responses and lung diseases in preterm infants suffering from respiratory distress syndrome (RDS) or bronchopulmonary dysplasia (BPD). However, none of the current clinical surfactants used for surfactant replacement therapy (SRT) to treat RDS contain SP-D. The interaction of SP-D with surfactant components, the potential of PS as a respiratory drug delivery system and the possibility to produce recombinant versions of human SP-D, brings the possibility of delivering clinical surfactants supplemented with SP-D. Here, we used an in vitro setup that somehow emulates the respiratory air-liquid interface to explore this novel approach. It consists in two different compartments connected with a hydrated paper bridge forming a continuous interface. We firstly analyzed the adsorption and spreading of rhSP-D alone from one compartment to another over the air-liquid interface, observing low interfacial activity. Then, we studied the interfacial spreading of the protein co-administered with PS, both at different time periods or as a mixed formulation, and which oligomeric forms of rhSP-D better traveled associated with PS. The results presented here demonstrated that PS may transport rhSP-D long distances over air-liquid interfaces, either as a mixed formulation or separately in a close window time, opening the doors to empower the current clinical surfactants and SRT.
CitationFront Bioeng Biotechnol. 2021 Jan 18;8:613276. doi: 10.3389/fbioe.2020.613276.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
The following license files are associated with this item:
- Creative Commons
- Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem.
- Authors: Arroyo R, Kingma PS
- Issue date: 2021 May 8
- Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant/tacrolimus formulations.
- Authors: Hidalgo A, Garcia-Mouton C, Autilio C, Carravilla P, Orellana G, Islam MN, Bhattacharya J, Bhattacharya S, Cruz A, Pérez-Gil J
- Issue date: 2021 Jan 10
- Surfactant protein-d inhibits lung inflammation caused by ventilation in premature newborn lambs.
- Authors: Sato A, Whitsett JA, Scheule RK, Ikegami M
- Issue date: 2010 May 15
- SP-D loaded PLGA nanoparticles as drug delivery system for prevention and treatment of premature infant's lung diseases.
- Authors: Attias Cohen S, Kingma PS, Whitsett JA, Goldbart R, Traitel T, Kost J
- Issue date: 2020 Jul 30
- Pulmonary surfactant and drug delivery: Focusing on the role of surfactant proteins.
- Authors: Guagliardo R, Pérez-Gil J, De Smedt S, Raemdonck K
- Issue date: 2018 Dec 10